公开(公告)号：US20250084149A1

公开(公告)日：2025-03-13

申请号：US18953634

申请日：2024-11-20

Applicant: Allogene Therapeutics, Inc. ,  Les Laboratoires Servier

Inventor： Cyril Alkis KONTO ,  Amina ZINAI

IPC: C07K14/705 ,  A61K31/664 ,  A61K31/7076 ,  A61K38/17 ,  A61K39/00 ,  A61K39/395 ,  A61P35/00 ,  C07K14/725 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783

Abstract: The present disclosure concerns dosages for the treatment of human patients susceptible to or diagnosed with a disease, such as cancer. Provided are methods for administering chimeric antigen receptor (CAR)-T cells. Also provided are compositions and articles of manufacture for use in the methods.

公开(公告)号：US12163169B2

公开(公告)日：2024-12-10

申请号：US16290388

申请日：2019-03-01

Applicant: Allogene Therapeutics, Inc.

Inventor： Andrew Ross Nager ,  Spencer Park ,  Javier Fernando Chaparro Riggers ,  Regina Junhui Lin ,  Thomas John Van Blarcom

IPC: C12N9/90 ,  A61K35/17 ,  A61K45/06 ,  C07K14/705 ,  C07K14/71 ,  C07K14/715 ,  C07K14/72 ,  C12N5/0783 ,  A61K38/00 ,  A61K48/00

Abstract: The present invention provides inducible chimeric cytokine receptors responsive to a ligand, e.g., a small molecule or protein, uses of such receptors for improving the functional activities of genetically modified immune cells, such as T cells, comprising the inducible chimeric cytokine receptors, and compositions comprising such cells.

公开(公告)号：US20240360196A1

公开(公告)日：2024-10-31

申请号：US18607387

申请日：2024-03-15

Applicant: ALLOGENE THERAPEUTICS, INC. ,  CELLECTIS

Inventor： Arvind RAJPAL ,  Shobha Chowdary POTLURI ,  Laurent POIROT ,  Alexandre JUILLERAT ,  Thomas Charles PERTEL ,  Donna Marie STONE ,  Barbra Johnson SASU

IPC: C07K14/705 ,  A61K35/17 ,  A61K39/00 ,  C07K14/725 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783

CPC classification number: C07K14/70503 ,  A61K35/17 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70578 ,  C07K16/2803 ,  C07K16/3069 ,  C12N5/0636 ,  A61K2039/5156 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2319/03 ,  C07K2319/70 ,  C07K2319/74 ,  C12N2510/00

Abstract: The invention relates to an inhibitory chimeric antigen receptor (N-CAR) comprising



an extracellular domain comprising an antigen binding domain,
a transmembrane domain and,
an intracellular domain
wherein the intracellular domain comprises an Immunoreceptor Tyrosine-based Switch Motif ITSM, wherein said ITSM is a sequence of amino acid TX1YX2X3X4, wherein
X1 is an amino acid
X2 is an amino acid
X3 is an amino acid and
X4 is V or I.

公开(公告)号：US12043655B2

公开(公告)日：2024-07-23

申请号：US16804917

申请日：2020-02-28

Applicant: Allogene Therapeutics, Inc.

Inventor： Regina Junhui Lin ,  Thomas John Van Blarcom ,  Siler Panowski ,  Barbra Johnson Sasu

IPC: C07K14/715 ,  A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K16/40 ,  C12N5/0783 ,  C12N7/00 ,  C12N15/86

CPC classification number: C07K14/715 ,  A61K35/17 ,  A61P35/00 ,  C07K16/40 ,  C12N5/0636 ,  C12N7/00 ,  C12N15/86 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/33 ,  C12N2740/15043

Abstract: Provided herein are constitutively active chimeric cytokine receptors (CACCRs). When present on chimeric antigen receptor (CAR)-bearing immune cells, such CACCRs allow for increased immune cell activation, proliferation, persistence, and/or potency. Also provided are methods of making and using the CACCRs described herein.

公开(公告)号：US20240085403A1

公开(公告)日：2024-03-14

申请号：US18450554

申请日：2023-08-16

Applicant: Allogene Therapeutics, Inc.

Inventor： Thomas Charles PERTEL ,  Ren SONG ,  Diego A. VARGAS-INCHAUSTEGUI ,  Garima YAGNIK ,  Houman DEHGHANI ,  Wenjing LI ,  Jose PENA

IPC: G01N33/50 ,  C12N5/0783 ,  C12N7/00 ,  C12Q1/6851 ,  C12Q1/70

CPC classification number: G01N33/5023 ,  C12N5/0636 ,  C12N7/00 ,  C12Q1/6851 ,  C12Q1/705 ,  C12N2501/24 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2710/16521

Abstract: The instant disclosure relates to methods for preventing, controlling and/or inhibiting the rare events of adventitious viral infection or viral replication/amplification after reactivation of latent viral infection during cell culture in the manufacturing process of cell-based drug products, including CAR T cell drug products. Also provided are in vitro cell culture models for HHV-6 latent infection and methods of making the same.

公开(公告)号：US20230287120A1

公开(公告)日：2023-09-14

申请号：US18308143

申请日：2023-04-27

Applicant: ALLOGENE THERAPEUTICS, INC. ,  PFIZER INC.

Inventor： Yi ZHANG ,  Thomas John VAN BLARCOM ,  Siler PANOWSKI ,  Silvia K. TACHEVA-GRIGOROVA ,  Barbra Johnson SASU

IPC: C07K16/28 ,  A61P35/00 ,  C12N15/63

CPC classification number: C07K16/2809 ,  A61P35/00 ,  C07K16/2887 ,  C12N15/63 ,  A61K2039/505

Abstract: Provided herein are DLL3 binding agents and chimeric antigen receptors (CARs) comprising a DLL3 binding molecule that specifically binds to DLL3; and immune cells comprising these DLL3-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using DLL3-specific CARs, and immune cells comprising DLL3-specific CARs.

公开(公告)号：US20220409665A1

公开(公告)日：2022-12-29

申请号：US17841041

申请日：2022-06-15

Applicant: Allogene Therapeutics, Inc.

Inventor： Elvin J. LAURON ,  Siler PANOWSKI ,  Barbra Johnson SASU ,  Cesar Adolfo SOMMER ,  Surabhi SRIVATSA SRINIVASAN ,  Thomas John VAN BLARCOM ,  Shanshan LANG

IPC: A61K35/17 ,  C07K16/28 ,  A61P35/00

Abstract: Provided herein are CD70-binding proteins comprising a CD70-binding domain and a transmembrane domain, engineered immune cells comprising the CD70-binding proteins, and methods of making and using the same. Also provided herein are engineered immune cells e.g. CAR (chimeric antigen receptor) T cells for administration to patients to treat cancer (e.g., solid tumors and hematologic tumors) and other unwanted conditions. The cells are engineered to functionally express a first antigen binding molecule e.g. a CD70 CAR and a second antigen binding molecule e.g. a second CAR that binds a target molecule characteristic of the cancer or other disease or unwanted condition. The cells may be further engineered to reduce the functional expression level of one or more of TRAC, CD52 and CD70. Also provided are methods of making and using the engineered cells, compositions and kits comprising them, and methods of treating by administering them.

公开(公告)号：US11326156B2

公开(公告)日：2022-05-10

申请号：US16177280

申请日：2018-10-31

Applicant: Allogene Therapeutics, Inc.

Inventor： Meritxell Galindo Casas ,  Thomas John Van Blarcom

IPC: C12N9/64 ,  C12N9/90 ,  A61K38/48 ,  A61K38/52 ,  A61K35/17 ,  C12N5/0783 ,  C12N11/18 ,  A61K31/7088

Abstract: Provided herein are modified caspase-9 polypeptides, and chimeric caspase-9 proteins containing the modified caspase-9 polypeptides. The disclosure further provides polynucleotides encoding these proteins, engineered host cells containing these polynucleotides and proteins, including host cells that co-express a chimeric antigen receptor, and methods of making and using the same.

公开(公告)号：US11072644B2

公开(公告)日：2021-07-27

申请号：US15525906

申请日：2015-11-09

Applicant: ALLOGENE THERAPEUTICS, INC. ,  CELLECTIS

Inventor： Arvind Rajpal ,  Shobha Chowdary Potluri ,  Laurent Poirot ,  Alexandre Juillerat ,  Thomas Charles Pertel ,  Donna Marie Stone ,  Barbra Johnson Sasu

IPC: C07K14/705 ,  C07K16/30 ,  A61K35/17 ,  C07K14/725 ,  C07K16/28 ,  C12N5/0783 ,  A61K39/00

Abstract: The invention relates to an inhibitory chimeric antigen receptor (N-CAR) comprising an extracellular domain comprising an antigen binding domain, a transmembrane domain, and, an intracellular domain wherein the intracellular domain comprises an Immunoreceptor Tyrosine-based Switch Motif ITSM, wherein said ITSM is a sequence of amino acid TX1YX2X3X4, wherein X1 is an amino acid X2 is an amino acid X3 is an amino acid and X4 is V or I.

公开(公告)号：US20200261503A1

公开(公告)日：2020-08-20

申请号：US16695894

申请日：2019-11-26

Applicant: Allogene Therapeutics, Inc.

Inventor： David Chang ,  Arun Balakumaran ,  Cyril Alkis Konto

IPC: A61K35/17 ,  A61P35/00 ,  A61K47/66 ,  C07K14/705

Abstract: Provided herein are BCMA CARs and CAR-T cells, methods of making, and using the same. In some embodiments, particular dosing regimens, redosing regimens, and combination regimens with lymphodepletion are provided, for the treatment and clinical management of multiple myeloma in subjects in need thereof.